Vistagen's Fasedienol Fails Phase 3 Primary Endpoint for Social Anxiety
VTGN is trading near its 52-week low of $0.43 (40% below the low) on elevated volume (2.0× avg).
Summary
Vistagen Therapeutics announced its fasedienol nasal spray failed to meet the primary endpoint in a Phase 3 trial for acute social anxiety disorder, with no treatment difference observed for secondary endpoints. This is a significant setback for a key pipeline asset, especially for a company that recently disclosed substantial doubt about its ability to continue as a going concern. While the company noted favorable safety and plans to discuss a new registrational pathway with the FDA, including a potential future Phase 3 trial, the immediate failure of a pivotal study's primary endpoint is a major blow to its drug development efforts and valuation.
At the time of this announcement, VTGN was trading at $0.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.2M. The 52-week trading range was $0.43 to $5.14. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.